奥西默替尼
医学
癌症研究
转录组
肺
肺癌
依托泊苷
腺癌
肿瘤科
表皮生长因子受体
内科学
恶性转化
雅普1
临床试验
细胞
间充质干细胞
亚临床感染
病理
组织微阵列
上皮-间质转换
癌症
基因表达谱
前瞻性队列研究
转移
作者
Lena Morrill Gavarró,Monica F. Chen,Àlvaro Quintanal-Villalonga,Yufei Deng,Liancheng Lu,Britney Forsyth,Sahil Sahni,Eric G. Sun,Swanand Rakhade,Rania Gaber Mohamed Aly,Meng Wang,Amin H. Sabet,P Solanki,Christina E. Wilson,Natasha Rekhtman,Sam E. Tischfield,Jake June-Koo Lee,Khadeja A. Moses,Linda Su Hyun Ahn,Clare Wilhelm
标识
DOI:10.1126/scitranslmed.aee6618
摘要
Although EGFR inhibitors are highly effective for treating EGFR- mutant lung adenocarcinomas ( EGFR + LUADs), resistance inevitably emerges, with histologic transformation to small cell lung cancer (SCLC) representing a particularly aggressive mechanism. Our prospective trial enrolled patients with EGFR + LUAD at high risk of transformation ( TP53 / RB1 -deficient) and treated them with first-line osimertinib combined with platinum and etoposide. Despite the addition of SCLC-directed chemotherapy, nearly half of patients (5 of 11) underwent SCLC transformation, with median progression-free survival of 11 months and overall survival of 33 months. Genomic and single-cell transcriptomic profiling of patient samples revealed clinical and subclinical plasticity associated with TP53 / RB1 comutations, including histological transformation to SCLC, as well as mesenchymal and squamous histologies. These changes in plasticity were linked to progressive disruption of the RB pathway, leading to altered chromatin accessibility and induction of neuronal differentiation and epithelial-to-mesenchymal transition transcriptional programs, further intensified by osimertinib treatment. These findings provide insights into the role of plasticity in mediating drug tolerance.
科研通智能强力驱动
Strongly Powered by AbleSci AI